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Abstract
Since growing tumors stimulate angiogenesis, via vascular endothelial growth factor
(VEGF), angiogenesis inhibitors (AIs, blockers of the VEGF signaling pathway) have been
introduced to cancer therapy. However, AIs often yielded only modest and short-lived gains
in cancer patients and more invasive tumor phenotypes in animal models. Combining anti-
VEGF strategies with lactate uptake blockers may boost both efficacy and safety of AIs. We
assessed this hypothesis by using the ex ovo chorioallantoic membrane (CAM) assay. We
show that AI-based monotherapy (Avastin®, AVA) increases tumor hypoxia in human CAM
cancer cell xenografts and cell spread in human as well as canine CAM cancer cell xeno-
grafts. In contrast, combining AVA treatment with lactate importer MCT1 inhibitors (α-
cyano-4-hydroxycinnamic acid (CHC) or AZD3965 (AZD)) reduced both tumor growth and
cell dissemination of human and canine explants. Moreover, combining AVA+AZD dimin-
ished blood perfusion and tumor hypoxia in human explants. Thus, the ex ovo CAM assay
as an easy, fast and cheap experimental setup is useful for pre-clinical cancer research.
Moreover, as an animal-free experimental setup the CAM assay can reduce the high num-
ber of laboratory animals used in pre-clinical cancer research.
Introduction
Angiogenesis, the formation of new blood vessels from pre-existing ones, is typically dormant
in adults. Yet, active angiogenesis represents a hallmark of many pathological progressions,
including diabetic retinopathy, rheumatoid arthritis, cardiac ischemia, psoriasis or tumor
growth and spread [1]. New capillaries are required for growth of the primary nodule beyond
constraints (i.e. size of ~1–2 mm3) [2]. However, the non-productive angiogenesis seen in
solid malignancies notoriously yields tortuous, dilated vessels with highly erratic blood flow
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and leaky endothelial lining [3], which is not necessarily associated with an increasing oxygen-
ation of the neoplasm [4]. In fact, even in areas of active angiogenesis a significant portion of
tumor tissue is perfused by deoxygenated blood [5]. As a result, there is a considerable spatial
and temporal heterogeneity in oxygen partial pressure (pO2) within the tumor. Consequently,
a highly proliferative cohort of actively respiring cells can be found in oxygenated areas, while
strongly glycolytic or even metabolically depressed and S-phase quiescent cells are nestled at
hypoxic, perinecrotic layers [6]. This alteration of metabolic activities, along with maximal ves-
sel-to-cell diffusion distances, renders cells in the deoxygenated areas prone to develop resis-
tance against blood-born cytotoxic drugs and irradiation [7]. The highly heterogeneous
composition of tumors with differing drug susceptibilities of individual cell cohorts needs to
be considered for more effective anticancer therapies [8].
Tumor hypoxia represents a potent stimulus for continued induction of several key angio-
genic cytokines, including the vascular endothelial growth factor (VEGF) [9, 10] and its endo-
thelial-specific receptors VEGFR1 (Flt1) and VEGFR2 (KDR/Flk1) [11, 12]. Stimulated
expression of VEGF and VEGFR1/R2 during low pO2 is, in part, conferred via the hypoxia
inducible transcription factors 1 and 2 (HIF-1/-2). VEGF binding to VEGFR1, VEGFR2 and
VEGFR3 represents a major signaling cascade to promote proliferation and differentiation of
the endothelial lineage in response to hypoxia [13] and marks an essential prerequisite of
metastasis (cf. above). Given the pivotal importance of VEGF and its receptor VEGFR2 in
angiogenesis, initial hopes were high to successfully combat cancer by inhibiting this pathway
[14–17]. However, mounting experience from clinical trials to date reveals the sobering fact
that VEGF-targeted therapy often prolongs overall survival of cancer patients by only months
and does not offer an enduring cure [18–20] or even failed entirely to reveal any evidence
regarding improved quality of life [20–22]. These clinical shortcomings of AI-based therapies
frequently arise from the development of resistance of the neoplasm to a given compound via
the recruitment of alternative signaling modes. Moreover, preclinical studies [14, 23–25] dem-
onstrated, in contrast to others [26, 27], enhanced metastasis in tumor-bearing mice treated
with Sunitinib or Avastin1. To produce robust therapeutic gains, combinations of antiangio-
genic strategies with measures for the inhibition of metastasis have repeatedly been suggested
since sole AI therapies are prone to raise the tumor´s aggressiveness by increasing tissue hyp-
oxia and tolerance of tumor cells to withstand it [14, 20].
Therefore, advancing therapies need to target not only the oxygenated/aerobe compartment
of the tumor adjacent to vascular structures via blood-born cytotoxins or AIs but also the ves-
sel-remote severely hypoxic areas. The α-cyano-4-hydroxycinnamic acid (CHC)-mediated
block of cellular lactate import via monocarboxylate transporter 1 (MCT1) was shown by Son-
veaux et al. to drive oxygenated tumor cells into aerobic glycolysis (Warburg effect) by using
glucose instead of lactate as primary energy substrate. According to the authors’ metabolic
symbiosis concept, oxygenated cells start to increasingly compete with hypoxic areas for glu-
cose, which will eventually kill particularly hypoxic cells prior to their development of thera-
peutic resistance and a highly metastatic phenotype [28]. Thus, combining CHC or AZD3965,
the next generation MCT1 inhibitor, with AIs (to starve oxygenated regions from nutrients),
might render hard-to-treat malignancies more susceptible to therapy and is conceptually a
very promising anticancer approach.
By applying this treatment strategy, we aimed to evaluate the applicability of the ex ovo cho-
rioallantoic membrane (CAM) assay as an animal-free experimental setup in an anti-cancer
approach. This assay complies with the 3R principles since according to Swiss legislation (Ani-
mal Protection Ordinance, Art 112) it is not considered an animal experiment when termi-
nated prior to embryonic day 14 as until then the CAM tissue remains free of pain-perceiving
fibers. The CAM develops during avian ontogenesis and serves as embryonic gas exchange
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organ. Because of its prominent vascularization it is used to study angiogenesis and angiogene-
sis inhibitors [29–31]. Moreover, the early chick embryo is immunodeficient, which allows
explantation and growth of cells and biopsies from different species without graft rejection in
CAM assays [32, 33]. In the ex ovo application, tumor grafts are directly accessible to manipu-
lations (i.e. topical or i.v. drug application) and data collection obtained by optical methods
(i.e. Laser speckle imaging). Hence, it is possible to observe and analyze vessel formation and
inhibition upon specific treatment with compounds upon explantation of cells or tissue or
even visualization with nanoparticles [30–32, 34]. The experimental time window between
explantation of the tumor cells and final measurements is 6–7 days. Thus, the assay is particu-
larly useful for rapid screens and safety measure assessments regarding angiogenesis, tumor
growth and cell dissemination of fast growing and spreading entities of cancer cells [35].
In our model tumor grafts, angiogenesis and the MCT1-driven lactate uptake were targeted
through application of Avastin1 (AVA) and CHC or AZD3965 (next generation inhibitor),
respectively. Since tissue hypoxia is prevalent in both human [28] and canine solid malignan-
cies [36–39] and the occurrence of metabolic symbiosis among oxic/hypoxic compartments of
the tumors was either demonstrated (human model tumors) [28] or can be anticipated to exist
(canine tumors), we assessed the efficacy of this combinatorial approach by grafting human
glioblastoma (U87), highly invasive breast carcinoma (MDA-MB231) as well as canine oral
melanoma (17CM98) and canine osteosarcoma (D17) cells onto the CAM surface. With this
setup, we were able to demonstrate 1) the tumor hypoxia and cell spread-promoting effect of
Avastin1 monotherapy as proof of principle, 2) the superiority of the combinatorial Avas-
tin1/CHC/AZD-based (AVA+CHC or AVA+AZD) therapy for effective targeting of oxygen-
ated/aerobe and hypoxic/glycolytic compartments of the tumor in inhibiting growth of
primary masses and cell dissemination and 3) the suitability of the CAM/explant approach as a
pre-clinical alternative for low cost, time saving and animal-free experimental setup.
Results
Selection of cell lines for tumor grafts
Tumor growth, solid mass formation and angiogenesis were scored after 6 days of inoculation
(d9-d14) for 13 different cell lines (Table 1). Human glioblastoma U87 (Fig 1), canine 17CM98
and canine D17 cell explants fulfilled the scoring criteria tumor growth (assessed as visible
increase in tumor mass; see Fig 2) together with active neovascularization (assessed as
increased blood flux around tumor (“halo”); see Fig 3) best and, therefore, were selected for all
subsequent experiments. Since in vivo glioblastomas scarcely metastasize outside the central
nervous system [40, 41] U87 explants were used as a rapidly growing, highly angiogenic tumor
model to analyze treatment-related changes in proliferation, perfusion and tissue oxygenation,
whereas tumor cell dissemination was assessed using MDA-MB231 breast cancer cells due to
their known strong invasive and metastatic potential in various settings [42, 43].
Tumor growth in response to drug treatment
For the final treatment of the CAM explants, we used 10mg/kg AVA and 60mg/kg CHC.
These dosages had been found to not exert any toxic effects in preliminary experiments on
embryos and cultured U87 cells (see S1 Fig).
Fig 2a, demonstrates on exemplary U87 grafts the tumor growth kinetics in response to six
days of AVA- and CHCmono- or combination-therapy compared to vehicle (CTRL).
Whereas AVA as well as CHCmonotherapy was able to diminish further tumor growth the
combination of AVA+CHC therapy induced significant shrinking of U87 model tumors. Data
shown in Fig 2b are based on image analysis and demonstrate that, by day 6 of the CAM assay,
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U87 CTRL grafts increased their volume by 269% ± 16.4%. In contrast, AVA and CHC treated
U87 tumors grew until d6 by 139% ± 11.89% and 122% ± 22.28%, respectively. In contrast,
AVA+CHC treated tumor grafts shrunk to 50% ± 41.13%. Thus, AVA and CHCmonotherapy
significantly inhibited the growth of primary masses, while combining AVA+CHC appears to
have an additive effect, resulting in significant tumor shrinkage.
Canine explants were treated with AVA in the same dosage as human explants (10mg/kg)
but with AZD3965 (2.5μM/egg), a next generation MCT1 inhibitor, that compared to CHC is
of higher specificity. Unfortunately, quantification of canine tumor growth required a different
experimental approach, since none of the canine tumors used grew as spherical masses as
human U87 explants did. Therefore, quantification was performed by qPCR using specific
primers against canine, human and chicken hypervariable D-loop region of mitochondrial
DNA. In human U87 grafts this measurement of tumor growth showed similar results com-
pared with image analysis (no further growth increase and even a slight tumor growth reduc-
tion, with overlapping error bars relative to CTRL tumors) for AVA treatment, the AVA
+AZD combinatorial intervention reduced growth to 46.96±10.45% if the CTRL tumor mass
was set to 100% (Fig 2c). Canine 17CM98 tumors responded to AVA treatment with a growth
reduction of 60.03±8.8%, to AZD treatment with 57.36±3.9% and to the combination of AVA
+AZD with 37.59±6.2% (Fig 2d). D17 explants responded to AVA with a 36.49±5.78% growth
reduction, to AZD with 56.74±15.64% and to AVA+AZD with 32.68±2.17% (Fig 2e). Thus,
AVA and CHC or AZDmonotherapies stalled or slightly reduced growth of primary masses,
while the combination of AVA with CHC or AZD potentiated shrinkage of the primary mass
in human as well as canine model tumors.
Tumor perfusion
Assessment of perfusion was performed using Laser speckle contrast imaging. In order to sep-
arate the CAM perfusion from that of the yolk beneath the CAM a polystyrene plastic strip
Table 1. Scoring of cell line performance on the CAM.
Type Cell Lines Proliferation Solid mass formation Angiogenesis Total score
Human melanoma 501 Mel + - - +
Human renal carcinoma RCC4 - - - -
Human renal carcinoma RCC4/VHL - - - -
Human hepatoma Hep3B + + + +++
Human breast carcinoma MCF7 + + + +++
Human breast carcinoma MDA-MB468 + - + ++
Human breast carcinoma MDA-MB231 + - - +
Human glioblastoma U87 + + + +++
Canine oral melanoma 17CM98 + + + +++
Canine osteosarcoma D17 + + + +++
Canine soft tissue sarcoma K9STS - - - -
Canine hemangiosarcoma HAS - - - -
Murine melanoma B16F10 + - + ++
Performance of tumor grafts from 13 different cell lines on the CAM. A positive score was given, for proliferation (observed growth: +; dried mass of dead cells: -), solid
mass formation (explant on CAM remains as dome-shaped coherent nodule: +; explant on CAM diffuses away from site of inoculation: -), and angiogenesis (observed
formation of capillary network as angiogenic „halo”seen in Laser-Doppler imaging (Fig 3): +; no increased flux: -). CAM suitability was found to be maximal for Hep3B,
MCF7, U87, 17CM98 and D17 cells, of which the latter three were selected for further analyses.
https://doi.org/10.1371/journal.pone.0251765.t001
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was inserted underneath the explant site. With this setup perfusion around and on the tumor
could be determined as a function of AVA (10mg/kg), CHC (60mg/kg) and AVA+CHC treat-
ment (Fig 3a and 3b) in human U87 model tumors as well as in canine 17CM98 and D17
explants treated with either AVA (10mg/kg), AZD (2.5μM/egg) or AVA+AZD (Fig 3c–3f).
Fig 1. Hematoxylin/Eosin staining of paraffin sections of U87 tumor grafts 6 days after inoculation. a: overview of
explant/CAM interface (scale bar: 200μm). b: detailed view showing tumor cells (arrows) invading CAM parenchyma
with hatched line indicating invasion front (scale bar: 25μm).
https://doi.org/10.1371/journal.pone.0251765.g001
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Most grafts reproducibly displayed a “halo” of ongoing angiogenesis around the tumor. For
human explants the size of the ‘halo’ was visibly reduced in parallel with the therapeutically
induced growth arrest or shrinkage of the tumor (Fig 2a and 2b). Fig 3b illustrates the continu-
ous reduction in blood flow at the tumor periphery when comparing CTRL treatment with
AVA or CHCmonotherapies and AVA+CHC combination, respectively. Again, the AVA
+CHC combinatorial treatment was most effective in diminishing perfusion to the explant to
background levels. Of note, perfusion at remote CAM control sites and embryonic angiogene-
sis was not affected by any treatment.
Fig 2. Tumor growth as function of drug treatment. a: Representative human U87 tumor explants subjected to treatments as indicated (from top left
to bottom right): CTRL (PBS, 10μl topically applied around explant); Avastin1 (AVA; i.v. injected: 10mg/kg); α-cyano-4-hydroxycinnamic acid (CHC,
60mg/kg; topically applied around explant); AVA+CHC (10mg/kg+60mg/kg). White arrows point to respective primary mass. b: Quantification of
tumor growth kinetics of human U87 by image analysis between day 2 (considered 100%) and 6 of CAM inoculation Day 0 = explant day. Data are
means ± SEM, n = 6. Statistical differences were tested with two-way ANOVA. ��� = p<0.001. c + d + e: Growth quantification using D-loop PCR data
obtained with human specific (c) and canine specific (d +e) primers normalized to D-loop amplicon abundance of chicken host tissue, as a function of
treatment (AVA, AZD and AVA+ AZD), relative to control (CTRL) conditions. Tumor explants (c: human U87; d: canine 17CM98 and e: canine D17)
were treated as indicated: control (PBS, 50μl i.v. injected, CTRL); Avastin1 (i.v. injected, 10mg/kg, AVA); AZD3965 (i.v. injected, 2.5μM/egg, AZD);
AVA+AZD (10mg/kg + 2.5μM/egg). Data in c), d) and e) are means ± SEM, n = 6. Statistical differences: one-way ANOVA, � = p< 0.05, �� =<0.02.
https://doi.org/10.1371/journal.pone.0251765.g002
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In canine explants, however, the various treatments were ineffective in reducing perfusion
into the mass (Fig 3c–3f) even though an increase in blood flow in the periphery of explants
(‘halo’) was reproducibly detected.
Assessment of tumor hypoxia
Local tissue hypoxia in response to AVA, CHC and AVA+CHC treatment of human U87
explants was assessed through staining of i.v. injected pimonidazole (cf. Fig 4a: brightfield and
4b: pimonidazole staining). Pimonidazole signals (red) quantified as ratio of maximal pimoni-
dazole intensity to average background intensity (Fig 4c) served as proxy for the severity of tis-
sue hypoxia, and % of pimonidazole-positive area to total tumor area (Fig 4d) as a measure for
the extent of tissue hypoxia. In spherical (dome-shaped) U87 grafts, pimonidazole staining
was absent in regions close to the air-exposed surface and for most of the highly vascularized
CAM/tumor interface (cf. Fig 1). In contrast, pimonidazole accumulated mainly within the
tumor’s core. Importantly, AVAmonotherapy significantly augmented intensity (+44% of
CTRL explants, Fig 4c), and moderately also area (+18% of CTRL explants, Fig 4d), of pimoni-
dazole staining in U87 tumors, which provides strong evidence for an Avastin1-dependent
increase in tissue hypoxia in these experimental tumor grafts. In contrast, CHC-only and AVA
+CHC reduced pimonidazole intensities to 90% (CHC) and 61% (AVA+CHC), and areas to
69% (CHC) and 74% (AVA+CHC), of CTRL explants, respectively. In line with the metabolic
symbiont concept [28], CHC-based formulations yielded a selective kill of hypoxic, pimonida-
zole-positive cells. With regards to explants of canine cancer cells, pilot experiments revealed
an intensified pimonidazole staining signal of cell cultures exposed to 16hrs hypoxia (0.1% O2)
when compared to normoxic cultures (16hrs, 21% O2). Unfortunately, the staining of canine
Fig 3. Blood perfusion of tumor explants. a + c + e: Representative perfusion images of tumor explants (a): U87; (c) 17CM98 and (e): D17, subjected
to the indicated treatments. Minimal flow = blue; maximal flow = red; see color scale on the right of panel a. Note the greenish ring (“halo”) of
angiogenic activity around the tumor grafts. b + d +f: Quantified flux of the tumor vicinity (b): U87; (d): 17CM98 and (f) D17, in response to indicated
treatments. Data are means ± SEM, (b) n = 6, (d) n = 5; (f) n = 8. Statistical differences were tested with two-way ANOVA. � = p< 0.05, �� =<0.02.
Scale bars = 1mm. AU = arbitrary units.
https://doi.org/10.1371/journal.pone.0251765.g003
PLOS ONE Treating human and canine tumor grafts on chick embryo chorioallantoic membranes
PLOSONE | https://doi.org/10.1371/journal.pone.0251765 May 17, 2021 7 / 20
xenografts with pimonidazole did not reveal visible treatment-dependent changes of tissue
hypoxia in 17CM98 and D17 grafts (S2 Fig). Similar results, unable to discern among treat-
ments, were obtained with carbonic anhydrase IX (CA IX) immune-histochemistry (S3 Fig).
Spreading of tumor cells
Using quantitative droplet digital PCR (ddPCR) in conjunction with zonal DNA extraction
(Fig 5a) and human- or chicken-specific mitochondrial DNA D-loop primer/probe pairs (Fig
5b and S1 Table) enabled us to quantify invasion of the highly aggressive MDA-MB231 cells
from the primary inoculation site into the surrounding CAM tissue as a function of treatment.
Regarding human cancer cells we had to switch from the non-metastasizing U87 to the actively
disseminating and invasive MDA-MB231 cells. The human/chicken D-loop signal ratio of the
tumor itself (zone 0) was set to 100%. Spreading of cells to zone 1 (directly adjacent to the
explant) resulted in a ratio of the human/chicken D-loop signal of 30.68±3.2% in CTRL, 56.35
±15.49% in AVA, 22.49±1.1% in CHC and 14.97±1.9% in AVA+CHC respectively. This indi-
cates maximal cell motility because of AVA application. A similar observation was made for
zone 2 (CTRL 1.8±0.4%, AVA 6.0±0.1%, CHC+CHC 1.5±0.7% and AVA+CHC 0.5±0.4%),
while negligible amounts of human DNA were detected in zone 3. Overall, these data indicate
that AVA treatment increases dissemination of MDA-MB231 cells as compared to CTRL and
other treatments. In contrast, and in comparison, to CTRL, cell spread was reduced with CHC
and even more with AVA+CHC treatment (Fig 5c). Regarding tumor grafts of canine cells, the
qPCR technique was used. Compared to control, we could show for both types of canine
explants an increased spreading tendency to zone 1 after AVAmonotherapy. Although relative
DNA expression was quite low for 17CM98 grafts, spreading of D17 cells into zone 1, always
Fig 4. Assessment of local tumor hypoxia. a: Representative brightfield image for illustration of different tumor regions. b: Representative images of
pimonidazole (Pimo) stained (red) cross sections of U87 tumors after CTRL (PBS), AVA, CHC and AVA+CHC treatments. Note the designated tumor
regions in the upper left Pimo-stained panel. Both the severity of tissue hypoxia (c), indicated by the intensity ratio of pimonidazole signals (maximal
Pimo signal / average tissue background) and the extent of tissue hypoxia (d), as depicted by the percent area ratio (pimo-positive area / total tumor
area), were quantified as function of treatment. Data are means ± SEM, n = 4. Statistical differences were tested with one-way ANOVA. � = p<0.05.
https://doi.org/10.1371/journal.pone.0251765.g004
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compared to zone 0, was 7.4±3.4% in CTRL, 16.92 ± 9.5% in AVA, 6.9 ± 0.3% in AZD and
2.6 ± 0.8% in AVA+AZD treated grafts. Similar to an aggressive human carcinoma cell, canine
explants showed a maximal dissemination tendency in response to AVA alone, while AZD
and even more AVA+AZD appeared to diminish cell dissemination from the primary mass,
an observation that was more obvious in D17 cell grafts (Fig 5d and 5e).
Metabolic symbiosis
Since the lactate exporting (MCT4) and importing (MCT1) transport proteins are crucially
important for the metabolic symbiont concept, expression of these proteins was assessed at
mRNA level in U87 human tumor explants using qPCR. By trend, expression of MCT1 and
MCT4 in U87 tumor grafts was higher after AVA monotherapy (Fig 6). Unfortunately, neither
the MCT1 nor the MCT4 transcript could be detected in canine tumor grafts. We, therefore
Fig 5. Dissemination of tumor cells in response to treatment. a: For quantification of cell dissemination genomic DNA (gDNA) and mitochondrial
DNA (mtDNA) were extracted fromMDA-MB231, 17CM98 and D17 tumor explants and nearby CAM tissue, divided into 4 zones (Zone 0, 1, 2, and 3;
2mm x 15mm stripes as indicated). b: Using human or chicken specific PCR primers against the hypervariable D-loop region of mtDNA (see S1 Table
for sequences and fluorescent labels) pilot PCRs revealed species-specific amplification of the D-loop amplicon in comparison with positive control
gDNA from humanMDA-MB231 cells and chicken liver. Left gel: PCR using human specific D-loop primers; right gel: PCR using chicken specific D-
loop primers. Loading of either gel: lane 1 = DNAMwmarker; lane 2 = DNA extraction (gDNA+mtDNA) from culturedMDA-MB231 cells; lane
3 = DNA extraction from chicken liver; lane 4 = DNA extraction from CAM-resident MDA-MB231 explant. c: Content of human DNA, normalized to
content of chicken (CAM derived) DNA, was quantified for zones 0–4 of MDA-MB231 explants using ddPCR with human or chicken specific D-loop
primers/probes, to estimate cell motility as function of treatment. For each treatment, zone 0 (explant periphery) was set to 100% of detected
MDA-MB231 DNA signals. Data are means ± SEM, n = 3. Statistical differences were tested with Wilcoxon rank-sum test. � = p<0.05. d + e: Spreading
behavior of 17CM98 and D17 cells, respectively, were quantified by qPCR with specific primers against mitochondrial D-Loop of canine (signal) and
chicken (normalization) sequences (S2 Table). Handling of the samples was exactly as described in (a). d: canine 17CM98 explants showed increased
spreading into zone 1 in response to AVAmonotherapy and in the combination therapy. e: canine D17 showed overall a higher spreading compared to
canine 17CM98. These explants demonstrated the superiority of the combination therapy in diminishing the spreading tendency of cells compared with
CTRL and AVA-monotherapy. Data are means ± SEM, d) n = 12 and e) n = 6. Statistical analysis: Kruskal-Wallis test, ns.
https://doi.org/10.1371/journal.pone.0251765.g005
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used the highly sensitive in situ hybridization technique (RNAscope1 ISH) with specific, man-
ufacturer-generated probes against canine MCT1 and MCT4 in cell cultures. With this stain-
ing procedure, an increase of MCT1 and MCT4 expression was clearly visible in hypoxic (1%
O2, 16h) compared to normoxic cell cultures (S4 and S5 Figs).
Discussion
The current study aimed to evaluate the applicability of the ex ovo chorioallantoic membrane
(CAM) assay as an animal-free experimental setup by targeting, individually and simulta-
neously, both aerobic and hypoxic compartments of model tumors through anti-VEGF and
lactate import blocking anti-MCT1 intervention strategies, respectively.
Fig 6. Quantitative PCR with human-specific primers against MCT1 andMCT4 as a function of treatment (AVA,
AZD, AVA+AZD) of human U87 tumor explants.MCT1 (a) and MCT4 (b) gene expression was normalized to β-
actin abundance and relative to control (CTRL). Data are means ±SEM, n = 4. Statistical analysis: Kruskal-Wallis test,
ns.
https://doi.org/10.1371/journal.pone.0251765.g006
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Using human U87 glioblastoma cells as xenografts (Table 1), solid tumor masses on the
CAM demonstrated, within a 6-day period of inoculation (d9-d14), increase in tumor volume
(Fig 2), active angiogenesis (Fig 3), development of local tissue hypoxia (Fig 4) and moderate
cell invasion into the chorioallantoic mesenchyme (Fig 5c). These points document that the
model reliably mirrors key features of growth and behavior of high-grade glioma in vivo.
Regarding canine 17CM98 oral melanoma and D17 osteosarcoma cells as xenografts we dem-
onstrated solid CAMmasses, reduced biomass accumulation by any treatment (Fig 2d and 2e),
active angiogenesis (indicated by ‘halo’; Fig 3) and a moderately intensified cell dissemination
tendency in response to AVAmonotherapy. In addition to techniques previously applied in
CAM studies [44–46], we employed the following novel methodological adaptations to deter-
mine the treatment´s impact on the following read-outs: i) real time perfusion in angiogenic
CAM tumor model by Laser-Speckle contrast imaging; ii) severity and extent of local tissue
hypoxia in CAM xenografts by i.v. injection of pimonidazole; iii) cell dissemination by zonal
DNA extraction in conjunction with human or canine specific qPCR. Growth, vascular func-
tional performance and tissue oxygenation of U87, 17CM98 and D17 grafts was recorded in
response to separate and combined application of non-toxic doses of the anti-VEGF antibody
Bevacizumab (Avastin1, AVA) and α-cyano-4-hydroxycinnamic acid (CHC) or AZD3965
(AZD), respectively. CHC inhibits the lactate importer MCT1 with roughly 10-fold selectivity
over other MCTs [28], whereas AZD is a specific MCT1 inhibitor [47]. By virtue of this anti-
VEGF/anti-MCT1 combinatorial strategy we anticipated to antagonize not only the oxygen-
ated/aerobe compartment of the tumor mass via AVA but also to starve the hypoxic cells via
CHC or AZD3965. Importantly, this selective kill of cells in the deoxygenated areas through
MCT1 inhibition will be accomplished without the need of the often efficacy-limiting delivery
of the drug into the hypoxic cells per se.
In line with these anticipations, we found the combination of AVA with CHC to be the
only mode of intervention successful in shrinking the primary mass of U87 grafts, roughly to
half the initial volume, whereas the monotherapies only prevented further mass accumulation
of the initial explant (Fig 2). The U87 growth kinetics agreed well with the observed progres-
sive reduction of perfusion (Avastin1+CHC = 51% reduction). Previous CAM experiments
with Bevacizumab supported our findings of the antiangiogenic effect, both in CAM and in
vivo assays [48]. Yet only the combination therapy was able to significantly reduce tumor per-
fusion down to CAM background levels, thus negating any tumor angiogenesis-related addi-
tional flux (Fig 3b). Of note, flux at tumor-remote CAM control sites and, allegedly,
embryonic angiogenesis was not affected by any of these interventions (Fig 3b), confirming
the non-toxic nature of the compounds and dosages (mono and combinatorial) in vivo. The
slowing of tumor growth and incomplete block of perfusion by AVA of the human U87 xeno-
grafts can be understood as remaining VEGF-independent angiogenesis signaling along with
increased tissue hypoxia, which emerged in AVA-treated glioblastoma mouse xenografts [49].
When we used U87 grafts on CAM, we similarly saw that a single intravenous injection of
AVA alone increased, not diminished, the intensity (44% increase relative to CTRL explants)
and extension (+18% increase) of pimonidazole-positive tumor hypoxia (Fig 4), a finding in
line with the known selection towards more hypoxia-tolerant and virulent secondary growth
as implicated by the above mentioned Avastin1- or Sunitinib treatments of tumor-bearing
mice [14, 23–25]. On the other hand, in U87 grafts and in support of a selective eradication of
deoxygenated tumor cells, the Avastin1+CHC combinatorial treatment effectively and signifi-
cantly diminished pimonidazole-positive hypoxia intensity (39% reduction) and area (26%
reduction) (Fig 4). The superior anticancer potency of anti-VEGF/anti-MCT1 combinatorial
interventions over respective monotherapies was thus demonstrated by its maximal efficacy in
diminishing growth, perfusion and tissue hypoxia within the primary mass of U87 CAM
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explants. In concordance with the pimonidazole staining, also the CA IX staining reveled a
similar trend of an AVA-induced increase of tissue hypoxia compared with CTRL (S3 Fig).
Unfortunately, U87 grafts did not produce any measurable spread and formation of micro-
metastatic foci in distant organs (e.g., liver) within the brief time window at hand. For this rea-
son, cell motility CAM assays were conducted with the strongly disseminating and invasive
human breast carcinoma line MDA-MB231 [42, 43].
Spreading of MDA-MB231 cells from the explant to adjacent zones 1 and 2 evidenced sig-
nificantly elevated cell motility in response to AVA-only application and further illustrates the
negative impact an anti-VEGF monotherapy might have. Yet, the data also revealed lesser-
than-CTRL cell dissemination after CHC-only and, particularly, after AVA+CHC combinato-
rial application (Fig 5c). However, the mechanistic basis for this motility-promoting and
-inhibiting effect by AVA and CHC-based protocols in MDA-MB231 tumor grafts must fun-
damentally differ from the metabolic symbiont concept [28] because the lactate importer
MCT1 is absent in MDA-MB231 cells due to hypermethylation-mediated gene silencing [28].
Future work thus needs to assess if a possible slowing of MCT4-mediated lactate export in
AVA-treated MDA-MB231 grafts translates into higher cellular concentrations of lactate,
which might drive the augmented motility and invasiveness seen in Fig 5c. For oxidative (but
not Warburg-type) tumors, physiological millimolar lactate levels were found to inhibit the
prolylhydroxylase domain 2 (PHD2)-driven hydroxylation and subsequent degradation of
HIF-1α, thus aiding in the activation of HIF-1 signaling, VEGF secretion and tumor angiogen-
esis even in normoxic compartments of the malignant mass [50]. These data solidify previously
established positive correlations between high-lactate tumors and high incidence of metastasis,
increased radiotherapy-resistance and poor clinical outcome [51, 52].
Treatment of the canine explants was conducted by applying AVA or AZD3965 alone and
in combination with one another. In agreement with the U87 data, tumor growth measure-
ments in canine explants also demonstrated reduced mass accumulation by both mono- and
the combination therapy (Fig 2c and 2d). While perfusion measurements of canine cancer cell
explants revealed an intensified perfusion in the vicinity of the grafted tumors compared to
remote area, this elevated blood supply proved to be completely refractory to any sort of treat-
ment (Fig 3d and 3f). Although Avastin1 is a humanized monoclonal antibody against VEGF,
it was shown to cross-react and bind also canine VEGF, with however a marginally reduced
affinity compared to human VEGF [53, 54]. We attempted to promote a more prominent
effect by applying more AVA (100mg/kg, i.e., 10x the dose used for Fig 3, S6 Fig) and repeated
the perfusion measurement. However, this dose not only reduced the blood flow in vicinity of
the tumors but also that of the embryonic background. Therefore, higher doses of AVA inter-
fered with the embryonal angiogenesis and would only confound our results on tumor perfu-
sion. On the other hand, the observation on 100mg/kg AVA reconfirms the applied
compound to exert no toxic effects on the embryo’s vasculature, since background flow was
only reduced when higher doses of AVA were applied but no reduction was observed in our
final experimental setup with 10mg/kg AVA. Regarding the treatment-refractive nature of the
canine explant vasculature, it should be stressed that general drawbacks of CAM assays may
well include a) nonspecific inflammatory reactions and b) ongoing embryonic physiological
angiogenesis as possible confounding effects on the vasoproliferative responses of the tumor
neovascularization. These responses may operate through different and VEGF-independent
signaling cascades [31].
Unfortunately, measurements of tumor tissue hypoxia with pimonidazole did also not
reveal any clear indication of tissue hypoxia in canine tumor explants (S2b and S2c Fig).
Absence of measurable hypoxia induction could be explained by the smaller masses and the
more two-dimensional growth pattern of canine tumors in comparison to U87 explants,
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which would aid oxygenation of the cancer cells through diffusion from ambient air. Of note,
accumulation of pimonidazole-based adducts was well illustrated in cultures of hypoxic canine
cancer cells (data not shown). This suggests tissue hypoxia to occur in CAM tumor models of
fast-growing masses as observed with U87 glioblastoma explants or at local sites within grafts
bulky enough to render diffusion of ambient oxygen insufficient.
Interestingly, the dissemination data showed an overall higher spreading tendency of D17
osteosarcoma compared with 17CM98 oral melanoma. Both cell types displayed an intensified
spreading from the primary mass into adjacent zones upon AVA-monotherapy when com-
pared with CTRL explants. Importantly, the combination therapy AVA+AZD reverted this
AVA-induced dissemination back to, and for D17 osteosarcoma cells even below, background
levels seen in the CTRL group.
Considering that also canine tumors are known to develop severe local hypoxia [55] with
increased VEGF plasma levels [38, 39, 56] it is anticipated for canine neoplasms too to repre-
sent metabolic symbionts of oxic/hypoxic compartments. Hence, a combination treatment
(AVA+AZD) could be beneficial to combat these cancers as well. In order to assess presence of
the metabolic symbiosis, the expression of the main transporters (MCT1 and MCT4) was mea-
sured in 17CM98 and D17 cell cultures and cell explants. By using RNAscope1 in situ hybrid-
ization on cultured cells an increase of both MCT1 and MCT4 mRNA was seen in 17CM98
oral melanoma cells in response to hypoxic exposure (0.2% O2, 16h) (S4 and S5 Figs). Unfortu-
nately, this expression was not detected in the CAM tumor explants of either canine cell type.
Reasons for this failed detection in CAM explants are currently unclear. Possibly the strong
oxygenation of the canine tumor grafts by ambient air impacted the expression, since nor-
moxic exposure of cultured 17CM98 and D17 cells also yielded very low levels of expression of
either transporter.
Taken together, we were able to evaluate the CAM/tumor assay presented here by simulta-
neously targeting tumor angiogenesis and hypoxic/glycolytic tumor cells. With this approach
we could assess tumor growth, measure blood flow, stain tissue hypoxia and quantify dissemi-
nation of human and canine cancer cells. Moreover, we demonstrate that VEGF-targeting
treatments, when applied as monotherapy, can increase tumor hypoxia and cell spread, a find-
ing clearly in line with the proposed selection of more hypoxia tolerant and metastasis-prone
malignant clonal variants in response to Avastin1- or Sunitinib1-related interventions. The
combination of Avastin1 with an inhibitor of the lactate trafficking system between hypoxic
and oxygenated tumor compartments was able to potently suppress cell dissemination in
human or dog cancer cells. Therefore, we demonstrated the suitability of the CAM/tumor
approach as a pre-clinical alternative for low cost, time saving and, most importantly, animal-
free experimental setup in cancer research.
Materials andmethods
Reagents
Cell culture media and supplements were purchased from GIBCO Switzerland. The Bevacizu-
mab anti-VEGF antibody Avastin1 (herein abbreviated: AVA) was purchased from Roche
(Genentech: Cat. # 2918877), α-cyano-4-hydroxycinnamic acid (Cat. # C-2020; herein: CHC)
from Sigma-Aldrich and AZD3965 (Cat. # HY-12750; herein: AZD) was purchased from
AstraZeneca.
Cell culture
Human glioblastoma U87 MG (HTB-14™), murine melanoma B16-F10 (CRL-6475™) and
canine osteosarcoma D17 (CCL-183™) cell lines were purchased from ATCC1 (American
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Type Culture Collection). Human breast cancer MDA-MB231 was a generous gift from Prof.
E. Dahl (Hospital of the RWTH Aachen University). Canine oral melanoma 17CM98 were
kindly provided by Prof. Dr. David Vail, University of Wisconsin-Madison. Canine soft-tissue
sarcoma K9STS and hemangiosarcoma HAS were kindly provided by Prof Dr. Carla Rohrer-
Bley, Vetsuisse Faculty Zurich. Human hepatoma (Hep3B), melanoma (501), renal clear cell
carcinoma with (i.e., RCC4) and without (i.e. VHL reverted cell line: RCC4/VHL) loss-of-
function mutation in the VHL tumor suppressor gene as well as breast carcinoma (MCF7,
MDA-MB468) cells were available as laboratory stocks from previous works [57, 58]. HEP3B,
U87, RCC4 and RCC4/VHL, MCF7, MDA-MB468 cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM), B16F10 cells in Eagle’s minimum essential medium (EMEM) and
501 melanoma cells in RPMI medium (RPMI Media 1640). Each medium contained high glu-
cose levels (4.5g/l), supplemented with 10% fetal bovine serum and 1% penicillin/streptomy-
cin. Selection pressure in RCC4 and RCC4/VHL cultures was maintained by addition of G418
antibiotic (0.5mg/ml). Canine cell lines (D17, 17CM98, K9STS and HAS) were cultured in
RPMI medium (RPMI Media 1640) supplemented with 10% fetal bovine serum, 1% penicillin/
streptomycin, 1% HEPES, 1% sodium pyruvate, 1% non-essential amino acid (NEAA) and 1%
GlutaMax. All cell lines were kept at 37˚C in humidified air with 5% CO2 and a pO2 of 141.6
mmHg ([O2] = 18.6% O2).
Ex ovo chick chorioallantoic membrane (CAM) assay
a) Preparing chick embryos. Fertilized eggs, (purchased from http://www.animalco.ch),
were placed for 72 hours into a cabinet incubator (HEKA, Rietberg, Germany) at 37.5˚C and
60–62% humidity [59]. On day 3 (d3) of chick development, eggs were cracked along the equa-
tor, opened and transferred into small, sterile plastic bowls (Thermoflex, Lonay, Switzerland)
while ensuring that yolk sac and embryo came to lie facing upwards. These ex ovo CAM cul-
tures were covered with Petri dish lids and kept at 37˚C and 60% humidity in Forma Scientific
incubators (Model-3336). All experiments were terminated before d14.5 prior to onset of pain
sensation in early development, which prevents CAM assays to be considered animal experi-
ments [60].
b) Selection of a suitable tumor cell line. On d9, 13 various human, mouse and canine
tumor cell lines, individually suspended in 15 μl of medium, were loaded onto the CAM to
induce tumor formation. Successful tumor establishment, analyzed by scoring growth, solid
mass formation and angiogenesis between d9-d14, resulted in the final selection of human
U87 glioblastoma (CAM load: 4 million cells), canine 17CM98 oral melanoma (4 million cells
+ 1/5 Matrigel) and canine D17 osteosarcoma (6 million cells + 1/5 Matrigel) as lines of inter-
est for further experiments.
Treatment with Avastin1 and CHC or AZD3965
One day after tumor cell inoculation on the CAM, assays were treated with control conditions
(i.e., CTRL; PBS (50μl)) or treated with the following experimental agents: a) AVA (10mg/kg;
intravenous injection); b) MCT1 inhibitor, either CHC (60mg/kg; topical application around
explant) or AZD3965 (2.5μM/egg; intravenous injection) as monotherapy (i.e. CHC; AZD); c)
the combination of AVA with either MCT1 inhibitor (i.e. AVA+CHC or AVA+AZD). Prior to
these treatments, AVA, CHC and AZD dosages were ascertained to exert no toxicity on cul-
tured cells and embryos (see S1 Fig).
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Quantification of tumor growth
U87 glioma cells were grafted onto the CAM (d9) and tumor growth was monitored by digital
imaging of tumors on d10, d12 and d14. Analysis of these images utilized MCID™ 7.0 software
(Ontario, Canada), yielding manually traced tumor borders and assumed spherical tumor vol-
ume (i.e. volume v = 4/3πr3, with r = 1/2
p
(D1xD2); D1 = short axis, D2 = long axis of tumor
area) [61]. The relative volume increase between day 2 (d10, set to 100%) and day 4 (d12) and
6 (d14) of AVA, CHC and AVA+CHC treated tumors was compared with PBS-treated control
explants.
Since canine tumor explants did not grow in a spherical fashion as the human U87 cells,
quantification of canine cell explants was done by qPCR. In this regard, canine cells were
explanted onto the CAM (d9), treated the next day, followed by tumor collection at d14 and
the isolation of genomic DNA, containing both nuclear and mitochondrial genomes. In order
to distinguish human or canine from chicken amplicons, species-specific primer pairs of the
hypervariable D-Loop region of mitochondrial DNA were generated (S2 Table). The abun-
dance of qPCR amplicons was measured in a semi-quantitative manner, with the ΔΔCT
method [62].
Quantification of tumor perfusion
Perfusion of the tumor explant and its periphery was measured on d14 using Laser-Speckle
perfusion imaging (moorFLPI, Moor Instruments, Germany). Interference by perfusion of the
underlying yolk sack was blocked by a polystyrene strip placed underneath the CAM. Perfu-
sion data were recorded, as function of treatment, at high resolution/low speed settings (10sec/
frame) in 8 different regions of interest (ROIs, each 4200-pixel large) on and around estab-
lished tumor grafts on the CAM. For assessing natural blood flow variations of the CAM, four
additional ROIs were placed on tumor-remote CAM sites.
Quantification of tumor hypoxia
The hypoxia marker pimonidazole (aka Hypoxyprobe™-1; NPI Inc., USA) was injected i.v.
(60mg/kg) into tumor-bearing embryos on d14, 20 min prior to sacrificing the embryo (i.e.
through injection of 100mM KCL) and harvesting the tumor explant. Dissected tumors were
fixed in 4% paraformaldehyde for 48h, cryo-protected in 30% sucrose for another 48h, frozen
in -20˚C cold isopentane and sliced into 14μm cryo-sections. Next, sections were blocked for
1h with 1% goat serum in PBS and incubated overnight with anti-pimonidazole rabbit IgG
(NPI Inc; pAb2627, 1/800 in PBS at 4˚C) and a Cy-3 conjugated secondary goat antirabbit
antiserum (Jackson ImmunoResearch, USA, 111.165.003; 1/700 in PBS for 1h at 37˚C). All sec-
tions were imaged using identical microscope, camera and acquisition settings to quantify
staining intensities and stained area with MCID software. As measure for severity of tissue
hypoxia the maximal signal of stained region was normalized to the average background signal
of the tissue (intensity ratio). Spatial extent of tumor hypoxia was defined as ratio of the stained
(“pimo-positive”) area per total tumor area (area ratio). Area ratios obtained from treated
tumors are expressed relative to that of control sections, set to 100%.
Tumor cell dissemination assay
Since U87 cells did not produce any measurable spread to distant organs with the brief experi-
mental time window of the assay, highly invasive MDA-MB231 breast carcinoma [42, 43] cells
were used. Thus, 6 days old MDA-MB231 grafts were subsequently sectioned into 2x15mm
stripes (Fig 5a). This way four spreading zones were defined with zone 0 representing the
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graft’s core and zones 1–3 the surrounding CAM at a distance of 2, 4 and 6mm from the
tumor periphery. In these zones the concentration of chicken and human DNA was deter-
mined using digital droplet PCR (QX100, ddPCR™, Biorad) with chicken and human specific
TaqMan primer/probe pairs that were directed against the hypervariable D-loop region of
human (i.e., MDA-MB231 cells) or chicken (i.e., amplification of host DNA as loading control)
mitochondrial DNA (for sequences, see S1 Table). Motility of MDA-MB231 cells was
expressed, for each zone, as percentage of human DNA compared to the chicken DNA.
Regarding canine sequences, however, TaqMan primer/probes designed against the canine
mitochondrial D-loop region did not amplify the anticipated PCR product. Therefore, spread-
ing behavior of the cells was quantified using semi quantitative PCR. Accordingly, 6d old
17CM98 and D17 grafts were sectioned as described above and amplicons of canine and
chicken of the mitochondrial D-Loop were quantified. Again, data was analyzed using the
ΔΔCT [62] method and zone 0 was set to 1. Gene expression of zone 1 to 3 were calculated rel-
atively compared with zone 0.
Metabolic symbiosis
To gain insight into the metabolic aspect of the treatment specific primers against human
MCT1 and MCT4 (28) were used. Reference primers against β-actin were used for amplicon
normalization (S2 Table). Expression of the transporters were quantified by qPCR and ana-
lyzed using the ΔΔCTmethod [62].
Statistical analysis
Results are expressed as mean values ± standard error of the mean of at least 3 independent
experiments. Statistical analysis was performed with GraphPad Prism 8 (GraphPad Software,
USA). Normal distribution of data population was tested using Shapiro-Wilk test and signifi-
cance determined by one-way ANOVA, Kruskal-Wallis test, Wilcoxon rank-sum test or two-
way ANOVA for comparison between different treatment groups. Tukey or Dunn’s post-hoc
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